In an attempt to identify novel nucleoside phosphoramidate analogues for improving the anti-HCV activity of 2’-C-Me-uridine, we have synthesized for the first time a series of L-glutamic acid, L-serine, L-threonine and L-tyrosine containing aryloxyphosphoramidate prodrugs of 2’-C-Me-uridine. Evaluation of their activity against HCV revealed that they displayed very potent anti-HCV activity, with EC50 values that are in the same range as of Sofosbuvir.status: publishe
The limited efficacy, in particular against the genotype 1 virus, as well as the variety of side eff...
We herein report the application of the phosphorodiamidate phosphate prodrug approach to a series of...
Given the impressive success of Gilead's Sofosbuvir, many laboratories, including ours, have explore...
In an attempt to identify novel nucleoside phosphoramidate analogues for improving the anti-HCV acti...
We report the application of our phosphoramidate ProTide technology to various 4′-substituted ribonu...
In view of a persistent threat to mankind, the development of nucleotide-based prodrugs against hepa...
A novel 2′,3′-dideoxy-2′-α-fluoro-2′-β-<i>C</i>-methyl-6-methoxy guanosine (<b>8</b>) and its phosph...
We herein report phosphorodiamidates as a significant new phosphate prodrug motif. Sixty-seven phosp...
The search for new anti-HCV therapeutics continues, as current standard of care based on pegINF and ...
We have previously reported the power of combining a 5′-phosphoramidate ProTide, phosphate pro-drug,...
Among the many prodrug approaches aimed at delivering nucleoside monophosphates into cells, the phos...
Hepatitis C virus infection constitutes a serious health problem in need of more effective therapies...
Novel phosphoramidate ProTides derived from 4′-azidoinosine have been prepared and evaluated in the ...
β-2′-C-Methyl purines (1, 2) are known inhibitors of hepatitis C virus (HCV). We herein report the s...
New 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidine (PMEO-DAPy) and 1-[2-(phosphonomethoxy)ethy...
The limited efficacy, in particular against the genotype 1 virus, as well as the variety of side eff...
We herein report the application of the phosphorodiamidate phosphate prodrug approach to a series of...
Given the impressive success of Gilead's Sofosbuvir, many laboratories, including ours, have explore...
In an attempt to identify novel nucleoside phosphoramidate analogues for improving the anti-HCV acti...
We report the application of our phosphoramidate ProTide technology to various 4′-substituted ribonu...
In view of a persistent threat to mankind, the development of nucleotide-based prodrugs against hepa...
A novel 2′,3′-dideoxy-2′-α-fluoro-2′-β-<i>C</i>-methyl-6-methoxy guanosine (<b>8</b>) and its phosph...
We herein report phosphorodiamidates as a significant new phosphate prodrug motif. Sixty-seven phosp...
The search for new anti-HCV therapeutics continues, as current standard of care based on pegINF and ...
We have previously reported the power of combining a 5′-phosphoramidate ProTide, phosphate pro-drug,...
Among the many prodrug approaches aimed at delivering nucleoside monophosphates into cells, the phos...
Hepatitis C virus infection constitutes a serious health problem in need of more effective therapies...
Novel phosphoramidate ProTides derived from 4′-azidoinosine have been prepared and evaluated in the ...
β-2′-C-Methyl purines (1, 2) are known inhibitors of hepatitis C virus (HCV). We herein report the s...
New 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidine (PMEO-DAPy) and 1-[2-(phosphonomethoxy)ethy...
The limited efficacy, in particular against the genotype 1 virus, as well as the variety of side eff...
We herein report the application of the phosphorodiamidate phosphate prodrug approach to a series of...
Given the impressive success of Gilead's Sofosbuvir, many laboratories, including ours, have explore...